BRPI0514021A - métodos para aperfeiçoamento de biodisponibilidade de um inibidor de renina - Google Patents

métodos para aperfeiçoamento de biodisponibilidade de um inibidor de renina

Info

Publication number
BRPI0514021A
BRPI0514021A BRPI0514021-8A BRPI0514021A BRPI0514021A BR PI0514021 A BRPI0514021 A BR PI0514021A BR PI0514021 A BRPI0514021 A BR PI0514021A BR PI0514021 A BRPI0514021 A BR PI0514021A
Authority
BR
Brazil
Prior art keywords
bioavailability
methods
inhibitor
renin inhibitor
improving
Prior art date
Application number
BRPI0514021-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Gian P Camenisch
Gerhard Gross
Isabel Ottinger
Daniel Wasmuth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0514021(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0514021A publication Critical patent/BRPI0514021A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0514021-8A 2004-08-03 2005-08-02 métodos para aperfeiçoamento de biodisponibilidade de um inibidor de renina BRPI0514021A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59870004P 2004-08-03 2004-08-03
PCT/EP2005/008369 WO2006013094A1 (en) 2004-08-03 2005-08-02 Methods for improving bioavailability of a renin inhibitor

Publications (1)

Publication Number Publication Date
BRPI0514021A true BRPI0514021A (pt) 2008-05-27

Family

ID=35056890

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514021-8A BRPI0514021A (pt) 2004-08-03 2005-08-02 métodos para aperfeiçoamento de biodisponibilidade de um inibidor de renina

Country Status (31)

Country Link
US (1) US7709532B2 (https=)
EP (2) EP1776099B1 (https=)
JP (1) JP5134366B2 (https=)
KR (1) KR20070040384A (https=)
CN (1) CN1993116B (https=)
AR (1) AR050043A1 (https=)
AT (1) ATE449601T1 (https=)
AU (1) AU2005268844B2 (https=)
BR (1) BRPI0514021A (https=)
CA (1) CA2572743C (https=)
CY (1) CY1109826T1 (https=)
DE (1) DE602005017905D1 (https=)
DK (1) DK1776099T3 (https=)
EC (1) ECSP077169A (https=)
ES (1) ES2335597T3 (https=)
HR (1) HRP20100064T1 (https=)
IL (1) IL180678A (https=)
MA (1) MA28821B1 (https=)
MX (1) MX2007001339A (https=)
MY (1) MY142180A (https=)
NO (1) NO20071142L (https=)
NZ (1) NZ552903A (https=)
PE (1) PE20060416A1 (https=)
PL (1) PL1776099T3 (https=)
PT (1) PT1776099E (https=)
RU (1) RU2404758C2 (https=)
SI (1) SI1776099T1 (https=)
TN (1) TNSN07038A1 (https=)
TW (1) TW200616610A (https=)
WO (1) WO2006013094A1 (https=)
ZA (1) ZA200610639B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
EP1927350A1 (en) * 2006-11-24 2008-06-04 Novartis AG Methods for improving bioavailability of a renin inhibitor
CA2769392A1 (en) 2009-07-31 2011-02-03 Sandoz Ag Method for the preparation of w-amino-alkaneamides and w-amino-alkanethioamides as well as intermediates of this method
WO2012010651A2 (en) 2010-07-23 2012-01-26 Sandoz Ag Method for the preparation of omega-amino-alkaneamides and omega-amino-alkanethioamides as well as intermediates of this method
WO2014168255A1 (ja) * 2013-04-12 2014-10-16 国立大学法人京都大学 巨核球の成熟化促進物質
WO2015035218A1 (en) * 2013-09-05 2015-03-12 Howard University Method of increasing the bioavailability of an hiv drug
JP6029621B2 (ja) * 2014-07-14 2016-11-24 ヤマサ醤油株式会社 血漿レニン活性の測定法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108499A (en) 1993-02-04 2000-02-29 Lilly Co Eli Mammalian influx peptide transporter
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
CA2224227A1 (en) 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CN1143680C (zh) * 1997-08-14 2004-03-31 阿旺蒂斯制药公司 增强非索非那定及其衍生物之生物利用度的方法
JP2003512443A (ja) * 1999-10-27 2003-04-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド タキサンをヒト患者に経口投与するための方法及び組成物
AU3808801A (en) * 2000-02-11 2001-08-20 Praecis Pharmaceuticals Incorporated Methods for enhancing the bioavailability of a drug
WO2001092468A2 (en) * 2000-05-31 2001-12-06 Rutgers, The State University Of New Jersey Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
GB0113663D0 (en) * 2001-06-05 2001-07-25 Novartis Ag Use of organic compounds
KR20040066177A (ko) 2001-12-19 2004-07-23 알자 코포레이션 친수성 거대분자의 경구 생체이용률을 증가시키기 위한제형 및 투여 형태
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
EP1501546B1 (de) * 2002-05-03 2012-10-10 Hexal AG Stabile pharmazeutische formulierung für eine kombination aus einem statin mit einem ace-hemmer
PT1517682E (pt) * 2002-06-28 2007-02-28 Speedel Pharma Ag Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
NZ549535A (en) * 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders

Also Published As

Publication number Publication date
CN1993116B (zh) 2011-04-13
JP2008508340A (ja) 2008-03-21
US20080108703A1 (en) 2008-05-08
MY142180A (en) 2010-10-15
AR050043A1 (es) 2006-09-20
DK1776099T3 (da) 2010-03-01
KR20070040384A (ko) 2007-04-16
ZA200610639B (en) 2008-05-28
ECSP077169A (es) 2007-02-28
PL1776099T3 (pl) 2010-05-31
CN1993116A (zh) 2007-07-04
IL180678A0 (en) 2008-03-20
RU2404758C2 (ru) 2010-11-27
US7709532B2 (en) 2010-05-04
MX2007001339A (es) 2007-03-27
HRP20100064T1 (hr) 2010-03-31
EP1776099B1 (en) 2009-11-25
ATE449601T1 (de) 2009-12-15
DE602005017905D1 (de) 2010-01-07
TNSN07038A1 (en) 2008-06-02
PT1776099E (pt) 2010-01-06
AU2005268844A1 (en) 2006-02-09
CA2572743A1 (en) 2006-02-09
JP5134366B2 (ja) 2013-01-30
IL180678A (en) 2011-04-28
CA2572743C (en) 2012-12-04
WO2006013094A1 (en) 2006-02-09
RU2007107850A (ru) 2008-09-10
EP1776099A1 (en) 2007-04-25
CY1109826T1 (el) 2014-09-10
SI1776099T1 (sl) 2010-03-31
MA28821B1 (fr) 2007-08-01
AU2005268844B2 (en) 2009-03-05
ES2335597T3 (es) 2010-03-30
NZ552903A (en) 2010-09-30
TW200616610A (en) 2006-06-01
EP2191823A1 (en) 2010-06-02
PE20060416A1 (es) 2006-06-09
NO20071142L (no) 2007-04-26

Similar Documents

Publication Publication Date Title
NO20083793L (no) Antistoffer mot amyloid-beta peptid
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA200800356A1 (ru) Лечение ингибиторами абсорбции холестерина на основе азетидинона и омега-3 жирными кислотами и их комбинированным препаратом
MX2010012270A (es) Inhibidores de dpp-iv para uso en el tratamiento de enfermedad hepatica grasa no alcoholica.
ATE469674T1 (de) 5-aminolävulinsäure-derivate zur behandlung von akne
MY161844A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2006099610A3 (en) Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy
CY1110162T1 (el) Φαρμακοτεχνικη μορφη και μεθοδοι για την αγωγη της θρομβοκυτταραιμιας
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
TNSN07038A1 (en) Methods for improving bioavailability of a renin inhibitor
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
CY1112620T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πεπτιδια βασικης πρωτεϊνης της μυελινης και ιατρικες χρησεις αυτων
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
WO2009027703A3 (en) Identifying organ damage
PL1889920T3 (pl) Sposób identyfikacji związków do terapii antynowotworowej in vitro
MX2009005247A (es) Metodos para mejorar la biodisponibilidad de un inhibidor de renina.
WO2007030360A3 (en) P13k inhibitors for the treatment of endometriosis
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal
MX2007009591A (es) Metodos para disposicion mejorada de farmacos.
WO2012037232A3 (en) Compositions, methods and kits for detecting and treating alzheimer's disease
BR0316010A (pt) Combinação
TH78450A (th) วิธีการสำหรับปรับปรุงการใช้ได้ทางชีววิทยา

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2266 DE 10/06/2014.